[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

86-021-23511999

Email address

jinchunlei@shhrp.com

Condition

Hormone-Dependent Prostate Cancer,Prostate Cancer

Treatment type

Interventional

Investigational product

Bicalutamide

Phase

Phase 3

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

ClinicalTrials.gov identifier

NCT03520478

Study number

SHR-3680-III-HSPC

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in the treatment of patients with hormone sensitive prostate cancer.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Age≧18 year, male;
  2. ECOG performance scale 0 to 1;
  3. Histologically or cytological confirmed prostate adenocarcinoma without neuroendocrine differentiation or small cell features ;
  4. Adequate hepatic, renal, heart, and hematological functions;
  5. Patients have given voluntary written informed consent before performance of any study-related procedure not part of normal medical care,with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
Exclusion criteria

  1. Subject has received any prior radiation therapy or surgery for prostate cancer, except 1 course of palliative surgical therapy if it was used at least 4 weeks prior to day 1;
  2. Previous use or are using a second-generation androgen receptor antagonist (enzalutamide, ARN-509, ODM-201), abiraterone, ketoconazole for prostate cancer, or other agents that will inhibit the production of androgens;
  3. Have participated in an interventional clinical trial or been treated with the following drugs in the past 4 weeks prior to day 1: 5-alpha reductase inhibitors, estrogen, progestin, and herbal products known to decrease PSA levels ;
  4. Evidence of brain metastasis or primary tumors;
  5. Planned to initiate any other anti-tumor therapies during the study;
  6. Unable to swallow, chronic diarrhea and intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption; Clinically significant cardiovascular diseases;
  7. History of seizure or certain conditions that may predispose to seizure;
  8. Severe concurrent disease and infection that, in the judgment of the investigator, would make the patient inappropriate for enrollment.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site